Yes, systemic corticosteroids potently suppress peripheral eosinophil counts through multiple mechanisms including induction of apoptosis, down-regulation of chemotactic factors, and inhibition of proinflammatory mediators.
Mechanism and Magnitude of Suppression
Systemic corticosteroids cause rapid and profound suppression of peripheral eosinophils. The evidence demonstrates that corticosteroids induce eosinophil apoptosis directly, with steroid-treated eosinophils showing nuclear condensation, cell size reduction, and DNA fragmentation within 24-72 hours 1. This mechanism is particularly pronounced in eosinophils from patients with atopic conditions.
Time Course and Degree of Suppression
The suppression occurs rapidly and dramatically:
- Within 4 hours: Eosinophil counts drop by approximately 95% following a single intravenous dose of methylprednisolone 2
- Peak suppression: Occurs at 8 hours post-administration
- Duration: Counts remain suppressed for 24 hours and return to baseline by 72 hours 2
- Magnitude in real-world asthma treatment: After oral corticosteroid initiation (average 35 mg/day), eosinophil counts decreased by 30-36% at one month, with higher baseline counts showing greater absolute reductions 3
Clinical Context Across Diseases
Eosinophilic Esophagitis
Systemic corticosteroids effectively resolve eosinophilic inflammation in multiple allergic diseases including asthma, eczema, and eosinophilic esophagitis 4. In EoE specifically, prednisone (1-2 mg/kg/day, maximum 60 mg) improved both clinical symptoms within 7 days and esophageal histology within 4 weeks in 20 of 21 children 4.
Asthma Exacerbations
In COPD exacerbations, data suggest that patients with elevated blood eosinophil counts (≥2%) respond more favorably to systemic corticosteroids, with treatment failure rates of only 11% compared to 66% in placebo 5. This demonstrates that the eosinophil-suppressing effect correlates with clinical benefit in eosinophilic phenotypes.
Tissue vs. Peripheral Eosinophils
Importantly, systemic corticosteroids suppress both peripheral blood eosinophils and tissue eosinophils. In chronic rhinosinusitis with nasal polyps, preoperative systemic steroids significantly reduced tissue eosinophil counts (mean difference -36.57 cells/HPF) 6. This dual suppression can interfere with histologic assessment when biopsies are obtained during or shortly after steroid treatment.
Important Clinical Caveats
Duration of Suppression Effect
The suppressive effect persists well beyond steroid discontinuation. In real-world asthma data, eosinophil counts had not returned to baseline levels several weeks after systemic corticosteroid discontinuation 3. Among patients who discontinued steroids within 7-21 days, only 21-26% had normalized eosinophil counts (<150 cells/µL) at one month post-index 3.
Paradoxical Responses
Not all patients respond uniformly. In a study of asthma exacerbations treated with prednisolone 30 mg/day for one week, some patients showed paradoxical responses with no decrease or even increased eosinophil counts despite treatment 7. These "paradoxical responders" had different cytokine profiles (persistent TSLP elevation and decreased miR-1 expression) and slower clinical recovery.
Biomarker-Guided Dosing
Recent evidence supports that baseline eosinophil counts can guide corticosteroid duration. In hospitalized asthma exacerbations, patients with eosinophils <300 cells/µL safely received only 3 days of prednisolone versus 5 days for those ≥300 cells/µL, with non-inferior outcomes and reduced cumulative steroid exposure in the non-eosinophilic group 8.
Practical Implications
When interpreting eosinophil counts for diagnostic or monitoring purposes:
- Obtain baseline counts before initiating systemic corticosteroids when possible
- If evaluating for eosinophilic conditions, wait at least 2-4 weeks after steroid discontinuation for accurate assessment 3
- Consider that even topical/inhaled steroids may have systemic absorption, though nasal/inhaled steroids do not significantly affect EoE treatment outcomes 9
The suppressive effect is dose-dependent and concentration-dependent 1, with higher doses producing more profound and sustained suppression. However, even low-dose regimens (4.2-18.6 mg/day for ≤7 days) can reduce tissue eosinophils, though effects may be less consistent 6.